What return do investors require to finance years of pre-revenue uncertainty? Traditional valuation frameworks offer limited guidance for answering this question in early-stage companies, where the dominant risks are often idiosyncratic and poorly captured by conventional measures such as beta.
In our previous article, What the Market Knows That WACC Doesn’t – CFA Institute Enterprising Investor, we introduced the MIDR — the discount rate that equates expected future cash flows, based on consensus forecasts, to the current stock price. Unlike the weighted average cost of capital (WACC), market-implied discount rate (MIDR) reflects the return investors are implicitly demanding, incorporating their assessment of risk, credibility, and future performance.
By examining MIDRs across a sample of publicly listed life sciences companies, we find that the market’s required return is closely linked to the timing of key milestones — particularly commercialization and initial profitability. Put simply, investors appear to demand compensation not only for uncertainty, but also for how long they must wait before uncertainty begins to resolve.
This insight is especially relevant for early-stage companies. Capital asset pricing model (CAPM)-based discount rates often struggle to capture the clinical, regulatory, and commercialization risks that dominate outcomes at this stage. As a result, investors and entrepreneurs often rely on broad rules of thumb or dated studies of venture capital returns. (See Plummer, Scherlis and Sahlman, and Sahlman and others). An MIDR analysis of publicly listed life sciences companies offers a market-based alternative and sheds new light on how investors price timing risk.
